Clinical Trials Directory

Trials / Completed

CompletedNCT00219609

Assessment Of Safety Of UK-390,957

A Phase 2 Multi-Center, Open Label Long-Term Extension Trial To Assess The Safety Of Oral Uk-390,957 Administered As Required In Adult Men With Premature Ejaculation

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
1,058 (planned)
Sponsor
Pfizer · Industry
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine whether UK-390,957 is a safe treatment for premature ejaculation.

Conditions

Interventions

TypeNameDescription
DRUGUK-390,957

Timeline

Start date
2005-01-01
Primary completion
2006-03-01
Completion
2006-03-01
First posted
2005-09-22
Last updated
2012-11-07

Locations

82 sites across 14 countries: United States, Australia, Austria, Canada, Czechia, France, Germany, Israel, Italy, Norway, Poland, Sweden, Turkey (Türkiye), United Kingdom

Source: ClinicalTrials.gov record NCT00219609. Inclusion in this directory is not an endorsement.